VXL Fundamental Analysis - VAXIL BIO LTD

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to VXL. VXL was compared to 24 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for VXL as it has an excellent financial health rating, but there are worries on the profitability. VXL has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

VXL had negative earnings in the past year.

In the past year VXL has reported a negative cash flow from operations.

In the past 5 years VXL always reported negative net income.

VXL had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

VXL's Return On Assets of -24.42% is fine compared to the rest of the industry. VXL outperforms 75.00% of its industry peers.

With an excellent Return On Equity value of -25.00%, VXL belongs to the best of the industry, outperforming 83.33% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-24.42%
ROE	-25%
ROIC	N/A

ROA(3y)-29.4%

ROA(5y)-42.62%

ROE(3y)-34.93%

ROE(5y)-66.34%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

VXL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, VXL has about the same amount of shares outstanding.

Compared to 5 years ago, VXL has less shares outstanding

There is no outstanding debt for VXL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -0.36, we must say that VXL is in the distress zone and has some risk of bankruptcy.

VXL's Altman-Z score of -0.36 is amongst the best of the industry. VXL outperforms 83.33% of its industry peers.

There is no outstanding debt for VXL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-0.36

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

VXL has a Current Ratio of 43.12. This indicates that VXL is financially healthy and has no problem in meeting its short term obligations.

VXL's Current ratio of 43.12 is amongst the best of the industry. VXL outperforms 100.00% of its industry peers.

A Quick Ratio of 43.12 indicates that VXL has no problem at all paying its short term obligations.

The Quick ratio of VXL (43.12) is better than 100.00% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	43.12
Quick Ratio	43.12

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for VXL have decreased strongly by -2355.56% in the last year.

EPS 1Y (TTM)-2355.56%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-4100%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VXL. In the last year negative earnings were reported.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

VXL does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

VAXIL BIO LTD

TSX-V:VXL (6/4/2025, 7:00:00 PM)

0.295

0 (0%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)04-24 2025-04-24

Earnings (Next)N/A N/A

Inst Owners0.01%

Inst Owner ChangeN/A

Ins Owners8.16%

Ins Owner ChangeN/A

Market Cap808.30K

Analysts0

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	1.13
P/tB	1.13
EV/EBITDA	N/A

EPS(TTM)-0.04

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)-0.09

FCFYN/A

OCF(TTM)-0.09

OCFYN/A

SpS0

BVpS0.26

TBVpS0.26

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-24.42%
ROE	-25%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-29.4%

ROA(5y)-42.62%

ROE(3y)-34.93%

ROE(5y)-66.34%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score5

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	43.12
Quick Ratio	43.12
Altman-Z	-0.36

F-Score5

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-2355.56%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-4100%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y22.83%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y57.22%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y57.22%

OCF growth 3YN/A

OCF growth 5YN/A

VAXIL BIO LTD (VXL.CA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens